A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

NCT03412773 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

684

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Tislelizumab
DRUG: Sorafenib

Sponsor

BeiGene